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Background: Cancer anorexia–cachexia is a debilitating condition frequently observed in NSCLC patients, characterized by
decreased body weight, reduced food intake, and impaired quality of life. Anamorelin, a novel selective ghrelin receptor agonist,
has anabolic and appetite-enhancing activities.
Patients and methods: ROMANA 3 was a safety extension study of two phase 3, double-blind studies that assessed safety and
efficacy of anamorelin in advanced NSCLC patients with cachexia. Patients with preserved Eastern Cooperative Oncology Group
2 after completing 12weeks (w) on the ROMANA 1 or ROMANA 2 trials (0–12weeks) could enroll in ROMANA 3 and continue
to receive anamorelin 100mg or placebo once daily for an additional 12w (12–24weeks). The primary endpoint of ROMANA 3
was anamorelin safety/tolerability (12–24weeks). Secondary endpoints included changes in body weight, handgrip strength
(HGS), and symptom burden (0–24weeks).
Results: Of the 703 patients who completed ROMANA 1 and ROMANA 2, 513 patients entered ROMANA 3 (anamorelin,
N¼ 345, mean age 62.0 years; placebo, N¼ 168; mean age 62.2 years). During ROMANA 3, anamorelin and placebo groups had
similar incidences of treatment–emergent adverse events (TEAEs; 52.2% versus 55.7%), grade3 TEAEs (22.4% versus 21.6%),
and serious TEAEs (12.8% versus 12.6%). There were 36 (10.5%) and 23 (13.8%) deaths in the anamorelin and placebo groups,
respectively; none were drug-related. Improvements in body weight and anorexia–cachexia symptoms observed in the original
trials were consistently maintained over 12–24weeks. Anamorelin, versus placebo, significantly increased body weight from
baseline of original trials at all time points (P< 0.0001) and improved anorexia–cachexia symptoms at weeks 3, 6, 9, 12, and 16
(P< 0.05). No significant improvement in HGS was seen in either group.
Conclusion: During the 12–24weeks ROMANA 3 trial, anamorelin continued to be well tolerated. Over the entire 0–24w treat-
ment period, body weight and symptom burden were improved with anamorelin.
Clinical trial registration numbers: ROMANA 1 (NCT01387269), ROMANA 2 (NCT01387282), and ROMANA 3 (NCT01395914).
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Introduction
Cancer anorexia–cachexia syndrome is a multifactorial, debilitating
condition frequently observed in patients with advanced cancer [1],
with a prevalence of 50%–80% [2]. It is characterized by reduced
food intake, negative metabolic changes [1], and decreased body
weight, primarily due to lean body mass (LBM) loss [3]. Cancer
cachexia negatively impacts patients’ quality of life (QOL), leads
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to decreased survival, and may reduce tolerance of, or responsiveness
to, therapy [4]. It frequently occurs in patients with NSCLC [5],
where the symptom burden includes substantial appetite and
weight loss, as well as fatigue [6, 7].
Ghrelin, the endogenous ligand of the ghrelin receptor, stimulates
multiple pathways that regulate body weight, LBM, appetite, and
metabolism [8, 9]. In patients with advanced cancer, intravenous
administration of ghrelin resulted in substantial caloric intake
and appetite increases, with no reports of drug-related adverse
events (AEs) [10, 11]. However, ghrelin’s clinical utility is
limited by its parenteral administration, combined with its
short half-life (<30 minutes).
Anamorelin is a novel, orally active, highly selective ghrelin
receptor agonist that activates multiple pathways involved in
regulating body weight, LBM, appetite, and metabolism [12].
Several randomized pilot or phase 2 trials have demonstrated
anamorelin’s safety and efficacy in increasing LBM, body weight,
and appetite in patients with various types of cancer [13–15].
Two international, double-blind phase 3 trials (ROMANA 1 and
ROMANA 2) assessed the efficacy and safety of anamorelin in
patients with advanced NSCLC and cachexia [16]. Anamorelin
treatment for 12 weeks was well tolerated and significantly
improved lean and fat mass, body weight, and anorexia–cachexia
symptoms; no effect was observed on handgrip strength (HGS)
[16]. Patients who completed ROMANA 1 or ROMANA 2 could
enroll in the ROMANA 3 extension study. This assessed the safety
of anamorelin, compared with placebo, for an additional
12 weeks (treatment period 12–24w), and efficacy across the
entire 24-week period, encompassing the ROMANA 1,
ROMANA 2, and ROMANA 3 study periods.
Materials and methods
Study design
ROMANA 3 (NCT01395914) was a double-blind, safety extension study
of the international phase 3 ROMANA 1 (NCT01387269) and ROMANA
2 (NCT01387282) trials. Patients enrolled in ROMANA 1 or ROMANA 2
were randomized (2 : 1) to 12 weeks of daily oral anamorelin 100 mg or
placebo. Patients with a preserved Eastern Cooperative Oncology Group
(ECOG) performance status 2 who completed dosing in either trial
could enroll in ROMANA 3. The trial was conducted at 70 hospital and
community sites in 18 countries (supplementary Table S1, available at
Annals of Oncology online). The protocol was approved by the
institutional review board or independent ethics committee at each
participating center and complied with the Declaration of Helsinki, the
International Ethical Guidelines for Biomedical Research Involving
Human Subjects, and Good Clinical Practice Guidelines.
Patients
Patients who had completed week 12 in the original trials and whom the
investigator considered suitable to receive an additional 12 weeks of study
treatment could enroll in ROMANA 3. Eligibility criteria for all patients
in the three trials were:18 years of age; histologically confirmed
unresectable stage III/IV NSCLC and cachexia (involuntary weight loss of
5% within the prior 6 months, or body mass index [BMI] <20 kg/m2);
ECOG performance status 2; and life expectancy of 4 months at
screening. Patients could receive concomitant chemotherapy. Those
receiving only parenteral nutrition, a concurrent investigational agent
other than the study drug, or prescription medications for increasing
appetite or treating weight loss (including corticosteroids) were
excluded. A summary of glucocorticoid-based concomitant medication
administered as antiemetics to patients participating in the ROMANA 3
trial is presented per treatment group in supplementary Table S2,
available at Annals of Oncology online. All patients provided written
informed consent.
Procedures
Patients enrolled in ROMANA 3 continued to receive anamorelin 100 mg
or placebo once daily for an additional 12 weeks (treatment period 12–
24 weeks); safety, body weight, and symptom burden were assessed every
4 weeks (16 weeks, 20 weeks, and 24 weeks). All treatment–emergent AEs
(TEAEs), study drug related or not, were graded according to the
National Cancer Institute Common Terminology Criteria for Adverse
Events, version 4.0. Body weight was assessed using a specific calibrated
scale. HGS (determined at 8 weeks and 12 weeks of ROMANA 3
[20 weeks and 24 weeks of the 0–24 weeks treatment period]) was
measured using hand-held dynamometers (Tracker Freedom
VR
Wireless
Grip Strength Testing System; JTECH Medical, Midvale, UT, USA).
Symptom burden was measured using the 12-item Anorexia/Cachexia
Subscale (supplementary Table S3, available at Annals of Oncology online)
of the Functional Assessment of Anorexia/Cachexia Treatment (FAACT)
tool [17].
Objectives
The primary objective was to evaluate safety/tolerability of anamorelin
over the ROMANA 3 exposure period. Secondary objectives included
evaluating effects of anamorelin on body weight, HGS, and symptom
burden over the 0–24 weeks treatment period comprising the ROMANA
1, ROMANA 2, and ROMANA 3 trials.
Statistical analyses
No formal sample size calculation was performed for this extension
study. Demographics and baseline characteristics were summarized using
descriptive statistics by treatment group and overall for the intent-to-treat
(ITT) population. Baseline (0w) of the original trials was defined as the last
measurement obtained before first administration of study drug. Safety was
assessed in all patients receiving either extension trial study drug.
Prespecified analyses included mean changes from baseline of original
trials in body weight and symptom burden at each visit of ROMANA 3
using a mixed-effects model for repeated measures. Treatment, ECOG
status (0–1 versus 2), BMI (>18.5 kg/m2 versus 18.5 kg/m2), age
(>65 years versus 65 years), gender, geographic region, chemotherapy/
radiotherapy status, weight loss over prior 6 months, and treatment by
time point interaction were considered fixed effects, and baseline a
covariate. The restricted maximum likelihood method was used.
Changes in HGS from baseline were analyzed using the same model.
Post-hoc analysis evaluated treatment differences for body weight and
symptom burden at each time point of the 0–24w treatment period of the
ROMANA 1, ROMANA 2, and ROMANA 3 trials using the mixed-effects
model for repeated measures. Least-squares means, corresponding standard
errors, and two-sided 95% confidence intervals (CIs) were derived for
between-group comparisons. All efficacy analyses were performed on the
ITT population. All statistical tests were two-sided; P values of 0.05 were
deemed statistically significant. SAS (v9.2 or above) was used for data
analysis.
Results
In total, 513 patients (anamorelin, N¼ 345; placebo, N¼ 168)
were enrolled in ROMANA 3; this comprised 228/352 patients
(65%) who completed ROMANA 1, and 285/351 (81%) who
completed ROMANA 2 (Figure 1). In total, 99.4% received study
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drug; the median number of days on treatment during
ROMANA 3 was 84.0 days for both treatment groups. Over the
entire 0–24w period, 221 patients had received anamorelin
(100 mg) for 24 weeks; the mean number of days on anamorelin
during this period was 161.1 days (85þ 76.1). Table 1 summarizes
demographic and baseline characteristics. There were no major
between-group differences, although the anamorelin group
included fewer patients with squamous cell carcinoma and more
with large cell histology than the placebo group (49.9% versus
53.6%, and 5.2% versus 2.4%, respectively). During the 12–24w
safety extension trial, the majority of patients received
chemotherapy (supplementary Table S4, available at Annals of
Oncology online) or radiotherapy, with similar proportions
between treatment arms.
TEAEs, study drug related or not, that occurred during the
ROMANA 3 extension trial (12–24w) are shown in Table 2.
Overall, 59 (11.6%) patients had an AE leading to death: 36
(10.5%) in the anamorelin group, and 23 (13.8%) in the placebo
group. No death was considered study drug related (supplementary
Table S5, available at Annals of Oncology online). The most
common drug-related TEAE during ROMANA 3 was hyperglycemia
(anamorelin: 1.2% versus placebo: 0.0%; Table 3). Four (1.2%)
anamorelin-treated patients reported hyperglycemia, in weeks 4
or 12 of ROMANA 3 (corresponding to 16w and 24w). Two
patients had grade 1 hyperglycemia (fasting glucose value higher
than the upper limit of normal [ULN] of 160 mg/dl), possibly
related to anamorelin; one patient had grade 2 hyperglycemia
(fasting glucose value higher than the ULN of 160–250 mg/dl),
possibly related to anamorelin. Hyperglycemia self-resolved
without anamorelin dose alteration or medical intervention in
each of the three patients. The fourth patient had grade 2
hyperglycemia deemed probably related to anamorelin on the
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Figure 1. CONSORT diagram of ROMANA 3. aPatients enrolled in ROMANA 3 stayed on their initial treatment arm (from ROMANA 1 or
ROMANA 2). bNo deaths were drug related. cIncluding the patients who did not receive study drug. Patients completing the study are
deﬁned as patients ﬁnalizing the week 12/day 85 visit. AE, adverse event; ITT, intent-to-treat.
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ROMANA 3 week 4 visit (16 weeks). This patient received no
hypoglycemic agents or dose alteration, and by study end
(24 weeks) the fasting glucose value decreased below the ULN of
160 mg/dl (grade 1 hyperglycemia).
Over the 0–24w treatment period, body weight increased in the
anamorelin (3.16 0.6 kg; CI: 1.8, 4.3) versus the placebo
(0.96 0.7 kg; CI:0.5, 2.3) group (treatment difference:
2.16 0.5 kg; CI: 1.3, 3.0). Anamorelin versus placebo significantly
improved body weight from baseline of original trials at all time
points (Figure 2A; P<0.0001). During the 0–24 weeks treatment
period, HGS worsened slightly in both groups (–0.86 0.9 kg
versus –0.66 1.0 kg). The Anorexia/Cachexia Subscale score
increased slightly more in the anamorelin (4.56 0.9 [CI: 2.7,
6.3]) versus the placebo group (3.26 1.0 [CI: 1.3, 5.2]; treatment
difference: 1.26 0.7 [CI: –0.1, 2.5]) over the 0–24w period, and
also at all time points during 0–24w (Figure 2B), with significant
treatment differences observed at weeks 3, 6, 9, 12, and 16
(P<0.05).
Analyzing changes in body weight and anorexia–cachexia
symptoms according to age, gender, ECOG performance status,
and BMI also suggested trends toward improvement following
anamorelin treatment. Considering changes to body weight from 0
to 24w, treatment differences ranged from 1.0 to 2.7 kg across the
different subgroups (anamorelin versus placebo) (supplementary
Table 1. Patient baseline demographics and clinical characteristics
ROMANA 3
Anamorelin
100mg
Placebo
(n5345) (n5168)
Mean age, years (SD) 62.0 (8.5) 62.2 (8.4)
Gender, n (%)
Male 262 (75.9) 125 (74.4)
Female 83 (24.1) 43 (25.6)
Geographic region, n (%)
North America 19 (5.5) 5 (3.0)
Western Europe 135 (39.1) 72 (42.9)
Eastern Europe and Russia 184 (53.3) 88 (52.4)
Australia 7 (2.0) 3 (1.8)
ECOG PS of original trial, n (%)
0 43 (12.5) 15 (8.9)
1 240 (69.5) 129 (76.8)
2 62 (18.0) 24 (14.3)
ECOG PS of extension trial, n (%)
0 31 (9.0) 11 (6.5)
1 245 (71.0) 126 (75.0)
2 69 (20.0) 31 (18.5)
Mean weight, kg (SD) 67.6 (13.0) 65.8 (13.5)
Weight loss over prior 6months, n (%)
10% of body weight 209 (60.6) 106 (63.1)
>10% of body weight 136 (39.4) 62 (36.9)
Mean BMI, kg/m2 (SD) 23.3 (3.6) 22.8 (3.6)
Mean FAACT A/CS Domain score (SD) 30.2 (8.3) 30.2 (8.3)
Mean non-dominant handgrip
strength, kg (SD)
32.5 (11.5) 32.2 (11.6)
Mean time from initial diagnosis,
months (SD)
18.2 (25.6) 14.6 (21.2)
Overall stage at study entry, n (%)
IIIA 34 (9.9) 18 (10.7)
IIIB 66 (19.1) 35 (20.8)
IV 244 (70.7) 115 (68.5)
Missing 1 (0.3) 0 (0.0)
Metastases at study entry, n (%)
Yes 244 (70.7) 115 (68.5)
No 101 (29.3) 53 (31.5)
Prior NSCLC treatment, n (%)
Chemotherapy/immunotherapy 106 (30.7) 46 (27.4)
Radiotherapy 54 (15.7) 23 (13.7)
Surgery 66 (19.1) 26 (15.5)
None 196 (56.8) 108 (64.3)
Concomitant therapya, n (%)
Chemotherapy/immunotherapy 197 (57.1) 98 (58.3)
Maintenance 19 (5.5) 11 (6.5)
Therapeutic 181 (52.5) 88 (52.4)
Adjuvant 1 (0.3) 0 (0.0)
Radiotherapy 41 (11.9) 18 (10.7)
ITT population. Baseline of the original trial was deﬁned as the last
measurement obtained prior to the ﬁrst dose of the original trial study
drug; for the extension trial, the baseline was deﬁned as the last meas-
urement obtained prior to the ﬁrst dose of the extension trial study
drug.
aConcomitant chemotherapy/immunotherapy or radiation therapy
included any chemotherapy/immunotherapy or radiation therapy
used on or after the ﬁrst dose date of the extension trial study drug
and up to and including 7 days after the date of the last dose of the
extension trial study drug.
BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group
performance status; FAACT A/CS, Functional Assessment of Anorexia/
Cachexia Treatment Anorexia/Cachexia Subscale; ITT, intent-to-treat;
NSCLC, non-small-cell lung cancer; SD, standard deviation.
Table 2. Summary of TEAEs (safety population) during the 12-week exten-
sion study (i.e. weeks 12–24 overall), whether related to study drug or
not
Adverse event category ROMANA 3
Anamorelin
100mg
Placebo
(n5343) (n5167)
TEAE, n (%)
1 TEAE 179 (52.2) 93 (55.7)
1 drug-relateda TEAE 12 (3.5) 2 (1.2)
1 chemotherapy/immunotherapy-
related TEAE
93 (27.1) 40 (24.0)
Patients with any grade 3–5 TEAE 77 (22.4) 36 (21.6)
Patients with any drug-relateda
grade 3–5 TEAE
0 (0.0) 0 (0.00)
Patients with any TEAE leading to
discontinuation
22 (6.4) 11 (6.6)
Serious TEAEs, n (%)
1 serious TEAE 44 (12.8) 21 (12.6)
1 drug-related serious TEAE 0 (0.0) 0 (0.0)
TEAEs of special interest, n (%)
Blood glucose increased 19 (5.5) 6 (3.6)
Cardiovascular events 13 (3.8) 4 (2.4)
Ischemic heart disease 4 (1.2) 0 (0.0)
Electrocardiogram 4 (1.2) 7 (4.2)
Edema 9 (2.6) 5 (3.0)
Hepatic disorders 22 (6.4) 6 (3.6)
Deatha, n (%) 36 (10.5) 23 (13.8)
aNo deaths were drug related.
TEAE, treatment–emergent adverse event.
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Figure S1, available at Annals of Oncology online); for anorexia–
cachexia symptoms, changes ranged from 0.6 to 2.2 points across
subgroups (anamorelin versus placebo), except the>65 years
subgroup, where the comparison favored placebo (supplementary
Figure S2, available at Annals of Oncology online). Lastly, patients
who continued in the ROMANA 3 safety extension trial had an
improvement in mean body weight change from baseline of
original trial (ROMANA 1 or ROMANA 2), whereas patients with
a decrease in body weight change from baseline opted not to
participate in ROMANA 3 (supplementary Figure S3, available at
Annals of Oncology online).
Discussion
These results demonstrate that anamorelin is well tolerated in
advanced NSCLC patients with cachexia over the 12–24w
treatment period that constituted the ROMANA 3 safety
extension study.
Anamorelin was well tolerated, and no new TEAEs were identi-
fied during ROMANA 3. Similar incidences of TEAEs, grade3
TEAEs, and serious TEAEs, study drug un-/related, were reported
for anamorelin versus placebo during the 12–24 weeks treatment
period; drug-related TEAE incidence was 3.5% versus 1.2%
(anamorelin versus placebo). The most common drug-related
TEAE was hyperglycemia, which is consistent with ghrelin’s
activity as a glucose metabolism regulator through multiple
pathways [18]. It is perhaps surprising that hyperglycemia was
not observed more frequently, given the positive energy balance
and presumed increased carbohydrate intake in the anamorelin
group, and considering that cachectic cancer patients tend to be
insulin resistant [19]. The present results concur with those
obtained in ROMANA 1 and ROMANA 2 [14], where the most
common drug-related TEAE reported was also hyperglycemia
(ROMANA 1: 5.3%; ROMANA 2: 4.2%). Both trials also had low
incidence of grade3 drug-related TEAEs in the anamorelin
group (0.9% and 2.7%, respectively) [16], while in ROMANA 3
no patient had any incidence of grade3 drug-related TEAEs.
Over the entire 0–24 weeks treatment interval anamorelin, but
not placebo, resulted in progressive increases in body weight in
ROMANA 1 and ROMANA 2 (0–12 weeks). Body composition
analysis by dual-energy X-ray absorptiometry confirmed that
increases in LBM and fat mass accounted for the improvement in
body weight [16]. Such changes may reflect a positive energy and
protein balance, and are consistent with attenuation of anorexia–
cachexia symptoms that could lead to increased food intake. In
ROMANA 3, no serial body composition analysis was performed
because it was considered an excessive patient burden. However,
given that the rate of weight change was similar during the 0–
12 weeks and 12–24 weeks treatment periods, it seems reasonable
that body composition changes observed in ROMANA 1 and
ROMANA 2 would be maintained in ROMANA 3. In the placebo
group no change from baseline in body weight over the 24 weeks
period was observed. The lack of significant decrease in body
weight in placebo-treated patients, which might be an expected
outcome in NSCLC patients with cachexia, may at least partly be
due to the good performance status of the majority of patients
enrolled. The observed effect might also be due to the patients’
response to anti-cancer treatment. Regarding reduced anorexia–
cachexia symptom burden leading to improved food intake, there
appears to be no attenuation of effect based on body weight
change at 24 weeks. The slight reduction in anamorelin-induced
improvement on appetite/cachexia symptoms at weeks 20 and 24
is unlikely to have significant impact on food intake and energy
balance. Alternatively, ghrelin receptor agonists may also increase
body weight, independently from their effects on appetite,
through other mechanisms such as decreased energy expenditure
[20, 21]. Anamorelin effects were preserved in each of the age,
gender, ECOG status, and BMI subgroup analyses. These effects
were similar in all subgroups, despite the fact that 75% of
patients enrolled in this study are males, a population with more
pronounced weight loss due to cancer anorexia/cachexia.
The lack of difference in anamorelin effect based on gender might
be at least partly explained by the results of a phase I study
performed in healthy volunteers [22]. This study indicated that
gender played no significant differences in the pharmacodynamic
responses of anamorelin (at a dose of 25 mg), as rapid and almost
identical increases in circulating growth hormone levels were
observed in both males and females following anamorelin
administration. As such, a preponderance of males in the current
Table 3. Summary of study drug-related TEAEs by system organ class and
preferred term (safety population)
System organ class
Preferred term
ROMANA 3
Anamorelin
100mg
Placebo
(n5343) (n5167)
n (%) n (%)
Patients with any drug-related TEAEs 12 (3.5) 2 (1.2)
Metabolism and nutrition disorders 5 (1.5) 0 (0.0)
Diabetes mellitus 1 (0.3) 0 (0.0)
Hyperglycemia 4 (1.2) 0 (0.0)
Gastrointestinal disorders 5 (1.5) 1 (0.6)
Dry mouth 0 (0.0) 1 (0.6)
Dyspepsia 1 (0.3) 0 (0.0)
Nausea 2 (0.6) 0 (0.0)
Vomiting 2 (0.6) 0 (0.0)
Skin and subcutaneous tissue disorders 3 (0.9) 0 (0.0)
Dermatitis bullous 1 (0.3) 0 (0.0)
Onychomadesis 1 (0.3) 0 (0.0)
Urticaria 1 (0.3) 0 (0.0)
General disorders and
administration site conditions
1 (0.3) 1 (0.6)
Fatigue 0 (0.0) 1 (0.6)
Malaise 1 (0.3) 0 (0.0)
Immune system disorders 1 (0.3) 0 (0.0)
Allergic edema 1 (0.3) 0 (0.0)
Investigations 1 (0.3) 0 (0.0)
Increased c-glutamyl transferase 1 (0.3) 0 (0.0)
Nervous system disorders 1 (0.3) 0 (0.0)
Headache 1 (0.3) 0 (0.0)
Blood and lymphatic system disorders 0 (0.0) 1 (0.6)
Thrombocytopenia 0 (0.0) 1 (0.6)
TEAE, treatment–emergent adverse event (whether study drug-related
to or not).
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study population does not appear to be clinically relevant with
respect to treatment effect.
Current therapies for cancer anorexia–cachexia have limited
efficacy and are associated with potential risks [23], particularly
in patients with advanced cancer. Neither corticosteroids nor
progestational agents increase LBM and, when given at high doses
over long periods, corticosteroids are specifically associated with
induction of frank muscle wasting. The shift to initiate anorexia–
cachexia management early during the disease trajectory, to
maintain improved QOL for a longer period [1], highlights the
need for therapies that can be safely administered over relatively
long intervals. In addition, treatments should also address
nutrition, by increasing food intake and stimulating anabolism, and
relieve symptom burden, by overcoming the cachexia-associated
catabolic drive and enhancing body weight.
The incidence of drug-related TEAEs in ROMANA 1 and
ROMANA 2 was low and remained low after 24-week exposure
to anamorelin in ROMANA 3. Thus, anamorelin appears suitable
for longer-term cachexia interventions that might also include
other modalities (e.g. exercise or nutritional support) [24]. These
results are clinically relevant to patients with advanced-stage,
metastatic disease, a population that undergoes significant
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Figure 2. Least-squares mean change (6SE) from baseline of original trials in (A) body weight and (B) FAACT Anorexia/Cachexia Subscale
Domain Score during 24weeks of treatment in patients enrolled in ROMANA 3. ITT population. aThe P value indicates a signiﬁcant difference
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cachexia-related weight loss [4]. In addition to improving the
negative symptoms of cancer cachexia, the positive effects on
body weight may help ease the emergent psychosocial distress
associated with substantial weight loss [25].
ROMANA 3 does have limitations. No measurements of LBM
or fat mass were taken, restricting conclusions about durability of
anamorelin’s effect on body composition over longer time points.
No measurements were performed to quantify patients’ caloric
intake and no food diaries were collected, which limits inferences
about anamorelin’s effect on food intake. Furthermore, not all
patients who completed the ROMANA 1 and ROMANA 2 trials
entered in the ROMANA 3 extension study. This might be
explained by the progression of disease to the extent to which the
patient does not fulfill all eligibility criteria of the ROMANA 3
extension study, established prior to study initiation. Other
possible explanations are patients’ own choice based on previous
efficacy results with anamorelin or the possibility of selective
attrition due to worsening health status, as would be anticipated
in patients with advanced NSCLC. Deterioration of the health
status may also obscure improvements in symptom burden.
Another potential limitation of this study is the fact that NSCLC
patients enrolled had a mean age of 62 years, somewhat
younger than the typical lung cancer patient, aged 70 years or
older [26, 27]. As such, that results of this study bear primary
relevancy for slightly younger patients with NSCLC and a good
performance status. Differences in patients recruitment rates
between sites may also constitute a study limitation: the highest
numbers of patients (>30 patients/site) were recruited at medical
sites in Poland, Russia, Ukraine, and Hungary, while the lowest
numbers were recruited at sites in the USA. A possible
explanation for this discrepancy is the higher frequency of
ongoing clinical studies in the USA in comparison with eastern
European countries, thus leading to more possibilities for the
patients and subsequently a lower enrollment rate.
In conclusion, in this safety extension trial of patients with an
average age of 62 years, suffering from advanced-stage NSCLC
and cachexia, anamorelin was well tolerated, exhibiting an AE
profile similar to that in ROMANA 1 and ROMANA 2, with no
new safety signals identified. Improvements in body weight
and anorexia–cachexia symptoms/concerns were consistently
maintained for the 12–24 weeks extension period, demonstrating
that anamorelin efficacy is maintained over a longer exposure
period.
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